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Escherichia coli is one of the most widely host systems used for production of 
recombinant proteins. Antibiotics are commonly used during bacterial fermentation, 
and the vast majority of expression vectors, particularly for E. coli, contain antibiotic 
resistance genes as selection markers. Despite being a powerful selection tool, their 
use has been considered unacceptable in many areas of biotechnology, as the 
recombinant protein production for therapeutic use and vaccines, by regulatory 
authorities. In fact,this selection system has several disadvantages, namely,the risks 
for human health due to thespread ofthe resistance genes,loss of selective pressure 
as a result of antibiotic degradation and the excessive metabolic burden exerted by 
the constitutive expression of the antibiotic resistance gene on the host cell. Those 
drawbacks can be stopped by using antibiotic-free expression systems, which 
represent lower production costs and, in many cases, permit to obtain highly desirable 
characteristics, such as the sharp increase in recombinant protein production.The 
novel fusion system presented in this study is composed by one low molecular weight 
moiety, the Fh8 fusion partner. Previous studies have demonstrated the ability of this 
fusion partner to improve soluble protein expression using antibiotic selection 
systems. Taking into account the advantages of producing recombinant proteins 
without antibiotics, the novel fusion partner was applied to an antibiotic-free system 
from Delphi Genetics in order to evaluate its contribute, as a solubility tag, on 
recombinant protein production. Using DNA recombinant technology, the sequence of 
the Fh8 partnerwas inserted into pStaby plasmids and the codifying genes for three 
target proteinswere genetically fused to the novel partner. The bio-productions were 
carried out on cultures of 100 mL and the resulting fusion proteins were analysed by 
SDS-PAGE and compared to the non-fused protein controls. Fusion proteins used in 
this work were purified using nickel affinity resins and quantified by Bradford. All fusion 
proteins presented higher soluble expression than the non-fused ones. Results from 
this work showedthat the Fh8 fusion system can be used in an antibiotic-free 
expression system, offeringan effective and safe methodology to produce soluble 
recombinant proteins in E. coli. 
  
